Company profile: NeoImmuneTech
pharmaphorum
NOVEMBER 29, 2022
By enabling strong CD8 T-cell infiltration in cold tumor tissues, NT-I7, a compound developed by NeoImmuneTech, is capable of promoting a microenvironment that contributes to clinical efficacy, when combined with a CPI. Amplifying and reinvigorating persistent T cell immunity has become a much-needed path to enhance anti-tumor efficacy.
Let's personalize your content